Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection
Copyright © 2014 Elsevier España, S.L.U. All rights reserved..
Triple combination regimens consisting of lopinavir/ritonavir (LPV/r) plus 2 nucleoside/nucleotide analogs continue to be a valid option in initial antiretroviral therapy. Other protease inhibitors boosted with ritonavir (and in future with cobicistat) have been introduced, as well as other non-nucleoside analogs (rilpivirin) and 3 integrase inhibitors. None of the new regimens have shown superiority over LPV/r or comparisons are lacking. Therefore, regimens including LPV/r continue to be recommended as initial first-line or alternative strategies in most treatment guidelines. Dual combinations with LPV/r (plus raltegravir or lamivudine) are described in another article and can provide a similar response rate to triple combinations, better tolerance, and an improved cost-efficacy ratio, both for initial therapy and in simplification strategies. In contrast, LPV/r or darunavir/r monotherapy does not seem an acceptable option in treatment-naïve patients and is becoming increasingly less acceptable in simplification strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 Suppl 3 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica - 32 Suppl 3(2014) vom: 15. Nov., Seite 2-6 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Eficacia del tratamiento antirretroviral de inicio basado en lopinavir/ritonavir más 2 análogos de nucleósidos/nucleótidos en pacientes infectados por el virus de la inmunodeficiencia humana-1 |
|---|
| Beteiligte Personen: |
Zamora, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.10.2016 Date Revised 30.12.2016 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/S0213-005X(14)70160-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM244907153 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM244907153 | ||
| 003 | DE-627 | ||
| 005 | 20231224135716.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/S0213-005X(14)70160-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0816.xml |
| 035 | |a (DE-627)NLM244907153 | ||
| 035 | |a (NLM)25542868 | ||
| 035 | |a (PII)S0213-005X(14)70160-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Zamora, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of initial antiretroviral therapy based on lopinavir/ritonavir plus 2 nucleoside/nucleotide analogs in patients with human immunodeficiency virus type 1 infection |
| 246 | 3 | 3 | |a Eficacia del tratamiento antirretroviral de inicio basado en lopinavir/ritonavir más 2 análogos de nucleósidos/nucleótidos en pacientes infectados por el virus de la inmunodeficiencia humana-1 |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2016 | ||
| 500 | |a Date Revised 30.12.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2014 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Triple combination regimens consisting of lopinavir/ritonavir (LPV/r) plus 2 nucleoside/nucleotide analogs continue to be a valid option in initial antiretroviral therapy. Other protease inhibitors boosted with ritonavir (and in future with cobicistat) have been introduced, as well as other non-nucleoside analogs (rilpivirin) and 3 integrase inhibitors. None of the new regimens have shown superiority over LPV/r or comparisons are lacking. Therefore, regimens including LPV/r continue to be recommended as initial first-line or alternative strategies in most treatment guidelines. Dual combinations with LPV/r (plus raltegravir or lamivudine) are described in another article and can provide a similar response rate to triple combinations, better tolerance, and an improved cost-efficacy ratio, both for initial therapy and in simplification strategies. In contrast, LPV/r or darunavir/r monotherapy does not seem an acceptable option in treatment-naïve patients and is becoming increasingly less acceptable in simplification strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a AIDS | |
| 650 | 4 | |a Antiretroviral therapy | |
| 650 | 4 | |a Antirretrovirales | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Inhibidores de la proteasa | |
| 650 | 4 | |a Lopinavir | |
| 650 | 4 | |a Protease inhibitors | |
| 650 | 4 | |a Ritonavir | |
| 650 | 4 | |a Sida | |
| 650 | 4 | |a VIH | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Reverse Transcriptase Inhibitors |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Gatell, José M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica |d 1993 |g 32 Suppl 3(2014) vom: 15. Nov., Seite 2-6 |w (DE-627)NLM01273425X |x 1578-1852 |7 nnns |
| 773 | 1 | 8 | |g volume:32 Suppl 3 |g year:2014 |g day:15 |g month:11 |g pages:2-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S0213-005X(14)70160-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 Suppl 3 |j 2014 |b 15 |c 11 |h 2-6 | ||